December 15, 2017 / 1:12 PM / a year ago

BRIEF-IntelGenx Receives Health Canada Clearance To Begin Phase 2a Study With Montelukast Versafilm

Dec 15 (Reuters) - IntelGenx Technologies Corp:

* INTELGENX RECEIVES HEALTH CANADA CLEARANCE TO BEGIN PHASE 2A STUDY WITH MONTELUKAST VERSAFILM(TM) IN MILD TO MODERATE ALZHEIMER'S DISEASE

* INTELGENX TECHNOLOGIES SAYS PHASE 2A PROOF OF CONCEPT CLINICAL STUDY WILL START SCREENING AD PATIENTS IN Q1 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below